Searchable abstracts of presentations at key conferences in endocrinology

ea0090p91 | Diabetes, Obesity, Metabolism and Nutrition | ECE2023

Vitamin D supplementation reduces oxidative stress caused by hyperuricemia in type 2 diabetes mellitus patients

Alfaqih Mahmoud A. , Ababneh Ebaa , Sater Mai

Introduction: It is suggested that hyperuricemia in type 2 diabetes (T2DM) patients causes reactive oxygen species (ROS) accumulation, which causes the destruction of beta cells of the pancreas and contributes to T2DM. This study aimed to analyze the relationship between vitamin D deficiency (which is reciprocally related to Serum Uric Acid (SUA) levels), hyperuricemia, and levels of ROS scavengers in T2DM patients, and to investigate the effect of vitamin D supplementation on...

ea0090ep319 | Diabetes, Obesity, Metabolism and Nutrition | ECE2023

Leptin reduces the risk of poor glycemic control in type two diabetes mellitus patients on metformin therapy

Alfaqih Mahmoud A. , Aljanabi Mukhallad , Ababneh Ebaa , Khanfar Mariam , Sater Mai

Purpose: Type two diabetes mellitus (T2DM) is a chronic disease of debilitating complications. Good glycemic control could delay disease progression and microvascular complications. Nonetheless, some patients cannot maintain glycemic control.Patients and Methods: We recruited 340 T2DM patients on metformin therapy and categorized them according to their HbA1c levels into patients with good vs poor glycemic control. The levels of serum leptin were measure...

ea0031p299 | Pituitary | SFEBES2013

The effect of mTOR blockers on japanese quail ovarian granulosa cell functions

Kadasi Attila , Maruniakova Nora , Kolesarova Adriana , Balazi Andrej , Hanusova Emilia , Kotwica Jan , Mai Antonello , Sirotkin Alexander V

The aim of our study was to elucidated the role of mTOR-dependent intracellular signalling pathway in control of ovarian functions. For this purpose, we have examine the effect of three mTOR inhibitors (resveratrol, curcumin and synthetic mTOR blocker MC 2183 – Mai et al. 20051, at the doses 0, 1, 10, 100 μg/ml) on apoptosis and steroidogenesis by cultured Japanese quail ovarian granulosa cells. The release of steroid hormones (progesterone and te...

ea0095p8 | Adrenal 1 | BSPED2023

When management becomes the source of my sorrow! (prolonged steroids’ side effects and adrenal insufficiency from the patient’s perspective)

Ali Mai

Introduction: An overview of a 14-year-old Duchenne muscular dystrophy patient who was subjected to steroid treatment and suffered greatly as a result. This case study illustrates how management effects can occasionally have a negative impact on our bodies via the lens of a patient. This event also shows that what’s important to patients might not always be the same as what’s important to medical professionals.Case hist...

ea0081p82 | Diabetes, Obesity, Metabolism and Nutrition | ECE2022

Irisin in pediatric patients with Prader Willi Syndrome: the role of body composition and glucose metabolism

Mai Stefania , Fintini Danilo , Mele Chiara , Convertino Alessio , Bocchini Sarah , Grugni Graziano , Aimaretti Gianluca , Vietti Roberta , Scacchi Massimo , Crino Antonino , Marzullo Paolo

Irisin is a myokine involved in the browning of white adipose tissue and in the regulation of energy expenditure, glucose tolerance and insulin sensitivity. It was previously demonstrated that obese adults with Prader-Willi syndrome (PWS) harbor lower irisin levels than individuals with common obesity. Significant associations seem to relate irisin to muscle mass, REE, insulin resistance and triglycerides and also the strongest independent predictors of irisin levels were PWS ...

ea0063p451 | Adrenal and Neuroendocrine Tumours 2 | ECE2019

Attributes valued by patients, health-care practitioners (HCPs) and caregivers using pre-filled delivery systems: a systematic literature review

Thanh Xuan-Mai Truong , Rohban Thomas , Ribeiro-Oliveira Jr Antonio

Background: The development of a new syringe for lanreotide Autogel, in conjunction with patients, caregivers and HCPs, identified and integrated several upgrades to the previous design that could improve patient care.Aims: To better understand which attributes are pertinent to users, and how user preferences can be optimally assessed, we conducted a systematic literature review of relevant studies of pre-filled devices.Methods: Pu...

ea0035p910 | Pituitary Clinical (<emphasis role="italic">Generously supported by IPSEN</emphasis>) | ECE2014

Relationship between early and longer-term tumour volume reduction (TVR) with primary lanreotide Autogel (LAN-ATG) therapy in treatment-naive acromegalic patients: post hoc analyses of the PRIMARYS study

Caron Philippe , Maisonobe Pascal , Thanh Xuan-Mai Truong , Bevan John

Introduction: PRIMARYS provided evidence for TVR with monthly LAN-ATG 120 mg in treatment-naïve acromegalic patients (63% achieved TVR ≥20% with a favourable safety profile). To help clinicians with therapeutic management of acromegaly, tumour responsive over time needs to be further explored.Methods: PRIMARYS was an international, multicentre, open-label, single-arm study of 90 treatment-naïve acromegalic patients with pituitary macroade...

ea0035p911 | Pituitary Clinical (<emphasis role="italic">Generously supported by IPSEN</emphasis>) | ECE2014

Tumour and hormonal response with lanreotide Autogel 120 mg in treatment-naive acromegalic patients: further post hoc data from the PRIMARYS study

Bevan John , Maisonobe Pascal , Thanh Xuan-Mai Truong , Caron Philippe

Introduction: The PRIMARYS study demonstrated primary treatment with lanreotide Autogel 120 mg could achieve favourable tumour and hormone response rates in a large cohort of acromegalic patients. Here, we further interrogate the PRIMARYS database on the relationship between the tumour volume responsiveness and hormonal control.Methods: PRIMARYS was an international, multicentre, open-label, single-arm study of 90 treatment-naïve acromegalic patient...

ea0016p522 | Obesity | ECE2008

Glucose-dependent insulinotropic polypeptide downregulates expression and enzyme activity of 11β-Hydroxysteroid Dehydrogenase type 1

Andres Janin , Gogebakan Ozlem , Mai Knut , Pfeiffer Andreas , Spranger Joachim

Introduction: 11β-hydroxysteroid dehydrogenase type 1 (11 β-HSD1) converts cortisone into its active metabolite, cortisol. Mechanisms regulating the promoter-activity of 11β-HSD1 are of considerable importance to understand the basics of intracellular cortisol, lipid and glucose metabolism. The incretine glucose-dependent insulinotropic polypeptide (GIP) has been suggested to affect insulin sensitivity. However, the mechanisms of this effect are unclear yet....

ea0094p95 | Neuroendocrinology and Pituitary | SFEBES2023

Pituitary apoplexy with a twist

Elamin Aisha , Pallai Shillo , Macinerney Ruth , Khalifa Mai , Went Richard

Introduction: Multiple myeloma (MM) is a haematological disorder characterised by an aberrant rise in monoclonal paraprotein. Intrasellar plasmacytomas can be infrequent MM manifestations. They are challenging to diagnose and frequently mimic pituitary adenomas; however rarely present with pituitary apoplexy. We describe a patient with pituitary apoplexy-like symptoms, subsequently diagnosed with MM, whose intrasellar mass entirely resolved after chemotherapy....